Nastech Announces Promotion of Gordon Brandt, M.D. to President
20 Diciembre 2007 - 7:30AM
PR Newswire (US)
BOTHELL, Wash., Dec. 20 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it
has promoted Gordon Brandt, M.D. to President of Nastech. Dr.
Brandt previously held the title of Executive Vice President,
Clinical Research and Medical Affairs. Dr. Steven Quay will remain
the Company's Chairman and Chief Executive Officer. "We are pleased
to promote Gordon to the position of President of Nastech as he has
been instrumental in progressing our technologies and programs over
the past five years and in his new role he will have increased
responsibilities in our business relationships and operations.
Gordon has been the architect in designing and conducting multiple
development programs which will yield Phase 2 results in 2008,"
stated Steven C. Quay, M.D., Ph.D., Chairman and CEO of Nastech.
"This move will position Gordon for more active leadership in
Nastech and allows me to increase my efforts on establishing MDRNA
as an independent company concentrating on the development of
RNA-based therapeutics, which we believe will eventually provide
greater focus for both companies and enhance shareholder value."
"Nastech has developed a strong clinical pipeline of innovative
therapeutics using our proprietary drug delivery technologies which
are aimed at providing patients with a safe and effective method of
administering their medications without an injection," stated
Gordon Brandt, M.D., President of Nastech. "I look forward to
advancing our business imperatives and clinical programs in the
therapeutic areas we have targeted including osteoporosis,
diabetes, and obesity." Dr. Brandt joined Nastech in November, 2002
serving as the Executive Vice President, Clinical Research and
Medical Affairs overseeing the drug development process including
formulation, analytical chemistry, process development,
preclinical, clinical, regulatory affairs and statistics. From 1997
to 2002, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a
developer of oncology drugs, where he held the positions of Vice
President, Clinical and Regulatory Affairs and Director of Medical
Affairs. Dr. Brandt graduated from Yale University with a B.S.
degree in engineering science, received an M.D. from the University
of California, San Francisco, and completed his residency training
in internal medicine at Kaiser Hospital in San Francisco. Dr.
Brandt has been working in the medical device, biologic, and drug
fields for over 25 years, and holds five U.S. patents. About
Nastech Nastech is a biopharmaceutical company developing
innovative products based on proprietary molecular biology-based
drug delivery technologies. Nastech and our collaboration partners
are developing products for multiple therapeutic areas including
osteoporosis, obesity, diabetes, autism, respiratory diseases and
inflammatory conditions. Additional information about Nastech is
available at http://www.nastech.com/. Nastech Forward Looking
Statements Statements made in this press release may be
forward-looking statements within the meaning of Federal Securities
laws that are subject to certain risks and uncertainties and
involve factors that may cause actual results to differ materially
from those projected or suggested. Factors that could cause actual
results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of
Nastech to obtain additional funding; (ii) the ability of Nastech
to attract and/or maintain manufacturing, research, development and
commercialization partners; (iii) Nastech's and/or a partner's
ability to successfully complete product research and development,
including preclinical and clinical studies and commercialization;
(iv) Nastech's and/or a partner's ability to obtain required
governmental approvals; and (v) Nastech's and/or a partner's
ability to develop and commercialize products that can compete
favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or
suggested in any forward-looking statements are contained in
Nastech's most recent periodic reports on Form 10-K and Form 10-Q
that are filed with the Securities and Exchange Commission. Nastech
assumes no obligation to update and supplement forward-looking
statements because of subsequent events. Contacts: Nastech Ed Bell
Director, Investor Relations (425) 908-3639 Russo Partners, LLC
David Schull (Media) (212) 845-4271 DATASOURCE: Nastech
Pharmaceutical Company Inc. CONTACT: Ed Bell, Director, Investor
Relations, Nastech, +1-425-908-3639, ; or Media, David Schull,
Russo Partners LLC, +1-212-845-4271 Web site:
http://www.nastech.com/
Copyright
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024